Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1955 1
1959 1
1960 1
1961 1
1962 2
1963 1
1964 3
1965 1
1966 2
1967 3
1968 1
1969 7
1970 2
1971 2
1972 1
1973 6
1975 1
1976 1
1995 1
1998 2
1999 2
2001 1
2002 1
2004 1
2005 1
2006 5
2007 1
2008 2
2009 4
2010 2
2011 2
2012 2
2013 3
2015 1
2016 2
2017 3
2018 5
2019 4
2020 4
2021 7
2022 4
2023 7
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

102 results

Results by year

Filters applied: . Clear all
Page 1
Ofatumumab versus Teriflunomide in Multiple Sclerosis.
Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Kappos L; ASCLEPIOS I and ASCLEPIOS II Trial Groups. Hauser SL, et al. N Engl J Med. 2020 Aug 6;383(6):546-557. doi: 10.1056/NEJMoa1917246. N Engl J Med. 2020. PMID: 32757523 Clinical Trial.
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators. Hauser SL, et al. N Engl J Med. 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21. N Engl J Med. 2017. PMID: 28002679 Free article. Clinical Trial.
Inhibition of CD40L with Frexalimab in Multiple Sclerosis.
Vermersch P, Granziera C, Mao-Draayer Y, Cutter G, Kalbus O, Staikov I, Dufek M, Saubadu S, Bejuit R, Truffinet P, Djukic B, Wallstroem E, Giovannoni G; Frexalimab Phase 2 Trial Group. Vermersch P, et al. Among authors: dufek m. N Engl J Med. 2024 Feb 15;390(7):589-600. doi: 10.1056/NEJMoa2309439. N Engl J Med. 2024. PMID: 38354138 Clinical Trial.
Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis.
Montalban X, Arnold DL, Weber MS, Staikov I, Piasecka-Stryczynska K, Willmer J, Martin EC, Dangond F, Syed S, Wolinsky JS; Evobrutinib Phase 2 Study Group. Montalban X, et al. N Engl J Med. 2019 Jun 20;380(25):2406-2417. doi: 10.1056/NEJMoa1901981. Epub 2019 May 10. N Engl J Med. 2019. PMID: 31075187 Clinical Trial.
Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP).
Butzkueven H, Kappos L, Wiendl H, Trojano M, Spelman T, Chang I, Kasliwal R, Jaitly S, Campbell N, Ho PR, Licata S; Tysabri Observational Program (TOP) Investigators. Butzkueven H, et al. J Neurol Neurosurg Psychiatry. 2020 Jun;91(6):660-668. doi: 10.1136/jnnp-2019-322326. Epub 2020 Mar 31. J Neurol Neurosurg Psychiatry. 2020. PMID: 32234967 Free PMC article.
Does initial high efficacy therapy in multiple sclerosis surpass escalation treatment strategy? A comparison of patients with relapsing-remitting multiple sclerosis in the Czech and Swedish national multiple sclerosis registries.
Hrnciarova T, Drahota J, Spelman T, Hillert J, Lycke J, Kubala Havrdova E, Recmanova E, Adamkova J, Mares J, Libertinova J, Pavelek Z, Hradilek P, Ampapa R, Stetkarova I, Peterka M, Martinkova A, Stourac P, Grunermelova M, Vachova M, Dufek M, Horakova D. Hrnciarova T, et al. Among authors: dufek m. Mult Scler Relat Disord. 2023 Aug;76:104803. doi: 10.1016/j.msard.2023.104803. Epub 2023 Jun 12. Mult Scler Relat Disord. 2023. PMID: 37329786
Titi monkey father-daughter bond-related behaviors explain stress response variability.
Witczak LR, Samra J, Dufek M, Goetze LR, Freeman SM, Arias-Del Razo R, Baxter A, Karaskiewicz C, Lau AR, Rothwell ES, Savidge LE, Ferrer E, Bales KL. Witczak LR, et al. Among authors: dufek m. Psychoneuroendocrinology. 2023 Nov;157:106362. doi: 10.1016/j.psyneuen.2023.106362. Epub 2023 Aug 10. Psychoneuroendocrinology. 2023. PMID: 37586274 Free article.
Is breastfeeding in MS harmful or not? An answer from real-world Czech data.
Hradilek P, Zapletalova O, Hanulikova P, Havrdova EK, Woznicova I, Mazouchova A, Drahota J, Lauer M, Stetkarova I, Valis M, Libertinova J, Stourac P, Adamkova J, Ampapa R, Vachova M, Dufek M, Martinková A, Peterka M, Recmanova E, Mares J, Horakova D. Hradilek P, et al. Among authors: dufek m. Mult Scler Relat Disord. 2023 Aug;76:104790. doi: 10.1016/j.msard.2023.104790. Epub 2023 Jun 16. Mult Scler Relat Disord. 2023. PMID: 37348317
102 results